Ultragenyx Pharma (RARE) PT Raised to $90 at Stifel
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St futures slip as oil surge puts markets on edge
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Ultragenyx Pharma (RARE) PT Raised to $59 at Morgan Stanley
August 7, 2018 7:14 AM EDTMorgan Stanley raised its price target on Ultragenyx Pharma (NASDAQ: RARE) to $59.00 (from $57.00) while maintaining a Equalweight rating.
... MoreUltragenyx Pharma (RARE) PT Raised to $80 at Wedbush
August 6, 2018 7:50 AM EDTWedbush raised its price target on Ultragenyx Pharma (NASDAQ: RARE) to $80.00 (from $71.00) while maintaining a Outperform rating.
... MoreUltragenyx Pharma (RARE) PT Raised to $85 at Piper Jaffray
August 3, 2018 6:01 AM EDTPiper Jaffray raised its price target on Ultragenyx Pharma (NASDAQ: RARE) to $85.00 (from $67.00) while maintaining a Overweight rating.
... MoreUltragenyx Pharma (RARE) PT Raised to $92 at Barclays
August 3, 2018 5:15 AM EDTBarclays raised its price target on Ultragenyx Pharma (NASDAQ: RARE) to $92.00 (from $74.00) while maintaining a Overweight rating.
... MoreUltragenyx Pharma (RARE) Posts Smaller-than-Expected Q2 Loss
August 2, 2018 5:06 PM EDTUltragenyx Pharma (NASDAQ: RARE) reported Q2 EPS of ($1.06), $1.03 better than the analyst estimate of ($2.09). Revenue for the quarter came in at $12.8 million versus the consensus estimate of $5.42 million.
For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.
... More